Hoth Therapeutics Expands Clinical Trial Phase II in Europe to Treat Cancer-Related Skin Toxicities Hoth Therapeutics has partnered with ICON Clinical Research to expand its Phase II clinical trial in Europe for HT-001, targeting skin toxicities in cancer patients.

Hoth Therapeutics Expands Clinical Trial Phase II in Europe to Treat Cancer-Related Skin Toxicities #None #Hoth_Therapeutics #HT-001 #ICON_Clinical